Novo Nordisk starts crucial trial of obesity tablet
While Novo Nordisk struggles to meet the demand for its injection-based treatment Wegovy in the US, the pharmaceutical company has started a phase IIIa trial of semaglutide as a tablet-based treatment for obesity, aiming for similar weight loss results.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT
On Monday, Novo Nordisk initiated a global phase IIIa trial of semaglutide in tablet form, as a treatment for obesity, the pharmaceutical company confirms to MedWatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
